329 related articles for article (PubMed ID: 29673395)
1. Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial.
Chabala C; Turkova A; Thomason MJ; Wobudeya E; Hissar S; Mave V; van der Zalm M; Palmer M; Kapasa M; Bhavani PK; Balaji S; Raichur PA; Demers AM; Hoddinott G; Owen-Powell E; Kinikar A; Musoke P; Mulenga V; Aarnoutse R; McIlleron H; Hesseling A; Crook AM; Cotton M; Gibb DM;
Trials; 2018 Apr; 19(1):237. PubMed ID: 29673395
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
4. Electronic pillbox-enabled self-administered therapy versus standard directly observed therapy for tuberculosis medication adherence and treatment outcomes in Ethiopia (SELFTB): protocol for a multicenter randomized controlled trial.
Manyazewal T; Woldeamanuel Y; Holland DP; Fekadu A; Blumberg HM; Marconi VC
Trials; 2020 May; 21(1):383. PubMed ID: 32370774
[TBL] [Abstract][Full Text] [Related]
5. Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP).
Seddon JA; Garcia-Prats AJ; Purchase SE; Osman M; Demers AM; Hoddinott G; Crook AM; Owen-Powell E; Thomason MJ; Turkova A; Gibb DM; Fairlie L; Martinson N; Schaaf HS; Hesseling AC
Trials; 2018 Dec; 19(1):693. PubMed ID: 30572905
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
[TBL] [Abstract][Full Text] [Related]
7. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771
[TBL] [Abstract][Full Text] [Related]
8. Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy.
Dawson R; Diacon AH; Takuva S; Liu Y; Zheng B; Karwe V; Hafkin J
Trials; 2024 Jan; 25(1):70. PubMed ID: 38243296
[TBL] [Abstract][Full Text] [Related]
9. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.
Dorman SE; Nahid P; Kurbatova EV; Goldberg SV; Bozeman L; Burman WJ; Chang KC; Chen M; Cotton M; Dooley KE; Engle M; Feng PJ; Fletcher CV; Ha P; Heilig CM; Johnson JL; Lessem E; Metchock B; Miro JM; Nhung NV; Pettit AC; Phillips PPJ; Podany AT; Purfield AE; Robergeau K; Samaneka W; Scott NA; Sizemore E; Vernon A; Weiner M; Swindells S; Chaisson RE;
Contemp Clin Trials; 2020 Mar; 90():105938. PubMed ID: 31981713
[TBL] [Abstract][Full Text] [Related]
10. Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children.
Turkova A; Wills GH; Wobudeya E; Chabala C; Palmer M; Kinikar A; Hissar S; Choo L; Musoke P; Mulenga V; Mave V; Joseph B; LeBeau K; Thomason MJ; Mboizi RB; Kapasa M; van der Zalm MM; Raichur P; Bhavani PK; McIlleron H; Demers AM; Aarnoutse R; Love-Koh J; Seddon JA; Welch SB; Graham SM; Hesseling AC; Gibb DM; Crook AM;
N Engl J Med; 2022 Mar; 386(10):911-922. PubMed ID: 35263517
[TBL] [Abstract][Full Text] [Related]
11. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.
Rose PC; Hallbauer UM; Seddon JA; Hesseling AC; Schaaf HS
Int J Tuberc Lung Dis; 2012 Dec; 16(12):1588-93. PubMed ID: 23032215
[TBL] [Abstract][Full Text] [Related]
12. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
13. Acceptability of a first-line anti-tuberculosis formulation for children: qualitative data from the SHINE trial.
Wademan DT; Busakwe L; Nicholson TJ; van der Zalm M; Palmer M; Workman J; Turkova A; Crook AM; Thomason MJ; Gibb DM; Seeley J; Hesseling A; Hoddinott G
Int J Tuberc Lung Dis; 2019 Dec; 23(12):1263-1268. PubMed ID: 31931909
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a medication monitor-based treatment strategy for drug-sensitive tuberculosis patients in China: study protocol for a cluster randomised controlled trial.
Lewis JJ; Liu X; Zhang Z; Thomas BV; Vassall A; Sweeney S; Caihong X; Dongmei H; Xue L; Yongxin G; Huan S; Shiwen J; Fielding KL
Trials; 2018 Jul; 19(1):398. PubMed ID: 30045757
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of intensified short course regimen and standard regimen for adults TB meningitis: a protocol for an open label, multi-center, parallel arms, randomized controlled superiority trial (INSHORT trial).
Inbaraj LR; Manesh A; Ponnuraja C; Bhaskar A; Srinivasalu VA; Daniel BD
Trials; 2024 May; 25(1):294. PubMed ID: 38693583
[TBL] [Abstract][Full Text] [Related]
16. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
Cevik M; Thompson LC; Upton C; Rolla VC; Malahleha M; Mmbaga B; Ngubane N; Abu Bakar Z; Rassool M; Variava E; Dawson R; Staples S; Lalloo U; Louw C; Conradie F; Eristavi M; Samoilova A; Skornyakov SN; Ntinginya NE; Haraka F; Praygod G; Mayanja-Kizza H; Caoili J; Balanag V; Dalcolmo MP; McHugh T; Hunt R; Solanki P; Bateson A; Crook AM; Fabiane S; Timm J; Sun E; Spigelman M; Sloan DJ; Gillespie SH;
Lancet Infect Dis; 2024 May; ():. PubMed ID: 38768617
[TBL] [Abstract][Full Text] [Related]
17. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis.
Berry C; du Cros P; Fielding K; Gajewski S; Kazounis E; McHugh TD; Merle C; Motta I; Moore DAJ; Nyang'wa BT
Trials; 2022 Jun; 23(1):484. PubMed ID: 35698158
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial.
Padmapriyadarsini C; Bhavani PK; Natrajan M; Ponnuraja C; Kumar H; Gomathy SN; Guleria R; Jawahar SM; Singh M; Balganesh T; Swaminathan S
BMJ Open; 2019 Mar; 9(3):e024363. PubMed ID: 30826761
[TBL] [Abstract][Full Text] [Related]
19. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
Tweed CD; Dawson R; Burger DA; Conradie A; Crook AM; Mendel CM; Conradie F; Diacon AH; Ntinginya NE; Everitt DE; Haraka F; Li M; van Niekerk CH; Okwera A; Rassool MS; Reither K; Sebe MA; Staples S; Variava E; Spigelman M
Lancet Respir Med; 2019 Dec; 7(12):1048-1058. PubMed ID: 31732485
[TBL] [Abstract][Full Text] [Related]
20. AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial.
Lawrence DS; Youssouf N; Molloy SF; Alanio A; Alufandika M; Boulware DR; Boyer-Chammard T; Chen T; Dromer F; Hlupeni A; Hope W; Hosseinipour MC; Kanyama C; Lortholary O; Loyse A; Meya DB; Mosepele M; Muzoora C; Mwandumba HC; Ndhlovu CE; Niessen L; Schutz C; Stott KE; Wang D; Lalloo DG; Meintjes G; Jaffar S; Harrison TS; Jarvis JN
Trials; 2018 Nov; 19(1):649. PubMed ID: 30470259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
